A Phase 1, Open-Label, Randomized, Cross-Over Study To Estimate The Effects Of Steady-State Cimetidine On The Pharmacokinetics Of A Single Dose Of PD 0332334 In Healthy Subjects.

Trial Profile

A Phase 1, Open-Label, Randomized, Cross-Over Study To Estimate The Effects Of Steady-State Cimetidine On The Pharmacokinetics Of A Single Dose Of PD 0332334 In Healthy Subjects.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2009

At a glance

  • Drugs Cimetidine; Imagabalin
  • Indications Anxiety disorders; Peptic ulcer
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 03 Mar 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 25 Feb 2009 Pfizer has decided to discontinue development of this drug for the treatment of generalised anxiety disorder, as reported in a media release.
    • 05 Feb 2009 Additional location identified USA as reported by ClinicalTrials.gov, last updated 5 Feb 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top